Loss of PTEN is associated with progression to androgen independence
- 22 February 2006
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 66 (9) , 895-902
- https://doi.org/10.1002/pros.20411
Abstract
BACKGROUND Progression to a lethal androgen‐independent (AI) stage of advanced prostate cancer is a critical clinical obstacle limiting patient survival. PTEN inactivation is frequently observed in advanced prostate cancer and correlates with a poor prognosis. However, the functional significance of PTEN inactivation in AI progression has not been demonstrated. METHODS PTEN expression was examined in benign, hormone naïve and AI human prostate cancer specimens, and in recurrent AI Shionogi tumors. The effect of antisense oligonucleotide (ASO)‐mediated PTEN downregulation in AI progression of the Shionogi tumor model was determined. RESULTS Significantly reduced PTEN expression was observed in AI versus benign and hormone naïve prostate tumors. Seven of 14 AI Shionogi tumors exhibited marked downregulation or complete loss of PTEN. ASO‐mediated PTEN inhibition reduced androgen‐withdrawal induced regression of Shionogi tumors and accelerated AI progression. CONCLUSIONS These data suggest that PTEN inactivation may play a role in progression to androgen independence. Prostate 66: 895–902, 2006.Keywords
This publication has 25 references indexed in Scilit:
- The activation of Akt/PKB signaling pathway and cell survivalJournal of Cellular and Molecular Medicine, 2005
- Human cancer, PTEN and the PI-3 kinase pathwaySeminars in Cell & Developmental Biology, 2004
- Specific Inhibition of PTEN Expression Reverses Hyperglycemia in Diabetic MiceDiabetes, 2002
- Up-regulation of Akt3 in Estrogen Receptor-deficient Breast Cancers and Androgen-independent Prostate Cancer LinesJournal of Biological Chemistry, 1999
- The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathwayProceedings of the National Academy of Sciences, 1998
- PTEN/MMAC1/TEP1 involvement in primary prostate cancersOncogene, 1998
- The Tumor Suppressor, PTEN/MMAC1, Dephosphorylates the Lipid Second Messenger, Phosphatidylinositol 3,4,5-TrisphosphateJournal of Biological Chemistry, 1998
- Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expressionProceedings of the National Academy of Sciences, 1998
- Effect of tumour progression on the androgenic regulation of the androgen receptor, TRPM-2 and YPT1 genes in the Shionogi carcinomaThe Journal of Steroid Biochemistry and Molecular Biology, 1994
- Prostate cancer. Primary hormonal treatmentCancer, 1993